Patents Assigned to Astella Pharma Inc.
-
Publication number: 20220379171Abstract: An exercise support device (10) includes: an acquisition unit (11A) that acquires a physical quantity indicating an execution degree of an exercise according to an exercise program indicating a predetermined self-weight exercise; a deriving unit (11B) that derives subsequent intensity of the exercise by using the physical quantity acquired by the acquisition unit (11A); and a presentation unit (11C) that presents the intensity derived by the deriving unit (11B).Type: ApplicationFiled: October 20, 2020Publication date: December 1, 2022Applicant: Astellas Pharma Inc.Inventor: Motohiro KANAYAMA
-
Publication number: 20220356207Abstract: An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells. The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.Type: ApplicationFiled: June 30, 2022Publication date: November 10, 2022Applicants: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima UniversityInventors: Hideki ENDO, Yukihito ISHIZAKA, Akira ISHIGURO, Tomoki TAKASHINA, Takashi YAMAMOTO, Tetsushi SAKUMA
-
Patent number: 11473071Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcription activator, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 104, 105, 135, 141, 153, 167, or 172 in the expression regulatory region of human Utrophin gene are expected to be useful for treating or preventing DUCHENNE muscular dystrophy or BECKER muscular dystrophy.Type: GrantFiled: May 14, 2021Date of Patent: October 18, 2022Assignees: ASTELLAS PHARMA INC., MODALIS THERAPEUTICS CORPORATIONInventors: Eiji Yoshimi, Katsuro Yoshioka, Tetsuya Yamagata, Yuanbo Qin, Iain Robert Thompson, Nidhi Khanna
-
Publication number: 20220275359Abstract: [Problem to be Solved] To provide a guide RNA. [Solution] A guide RNA for editing a target RNA sequence, comprising an antisense nucleotide sequence complementary to a portion of the target RNA sequence, a short-chain ADAR-recruiting nucleotide sequence, and at least one functional nucleotide sequence.Type: ApplicationFiled: July 31, 2020Publication date: September 1, 2022Applicants: Astellas Pharma Inc., Fukuoka UniversityInventors: Eiji YOSHIMI, Yukari MORIYA, Mariko MANDA, Masatora FUKUDA
-
Patent number: 11414456Abstract: The present application provides a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.Type: GrantFiled: December 10, 2018Date of Patent: August 16, 2022Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima UniversityInventors: Hideki Endo, Yukihito Ishizaka, Akira Ishiguro, Tomoki Takashina, Takashi Yamamoto, Tetsushi Sakuma
-
Publication number: 20220233721Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcriptional repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 127, SEQ ID NO: 46, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 133, SEQ ID NO: 137, SEQ ID NO: 117, or SEQ ID NO: 119 in an expression regulatory region of a human DMPK gene, are expected to be useful for treating muscular dystrophy.Type: ApplicationFiled: May 27, 2020Publication date: July 28, 2022Applicants: Astellas Pharma Inc., Modalis Therapeutics CorporationInventors: Eiji YOSHIMI, Tomoya OE, Tetsuya YAMAGATA, Keith M. CONNOLLY
-
Patent number: 11395852Abstract: The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.Type: GrantFiled: October 11, 2018Date of Patent: July 26, 2022Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbHInventors: Ugur Sahin, Özlem Türeci
-
Patent number: 11390652Abstract: It is intended to provide a fusion polypeptide that regulates the transcription of a target gene. The present inventors have provided a fusion polypeptide comprising: a cell-penetrating peptide; a DNA-binding polypeptide; and a transcriptional regulator.Type: GrantFiled: December 11, 2017Date of Patent: July 19, 2022Assignees: Astellas Pharma Inc., National Center for Global Health and Medicine, Hiroshima UniversityInventors: Hideki Endo, Yukihito Ishizaka, Takashi Yamamoto, Tetsushi Sakuma
-
Patent number: 11376328Abstract: Provided is a pharmaceutical composition in which the solubility and/or dissolution properties of a poorly-soluble drug can be improved. The pharmaceutical composition comprises a poorly-soluble drug, and polyvinyl alcohol having a saponification degree of 63 mol % or more and 67 mol % or less.Type: GrantFiled: April 27, 2018Date of Patent: July 5, 2022Assignee: Astellas Pharma Inc.Inventors: Takatsune Yoshida, Hiroyuki Kojima, Yoshiaki Umemoto, Sachie Namiki, Akira Takagi, Ken Shimada
-
Patent number: 11344589Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.Type: GrantFiled: April 30, 2020Date of Patent: May 31, 2022Assignees: National University Corporation Tottori University, Astellas Pharma Inc.Inventors: Takafumi Nakamura, Hajime Kurosaki, Motomu Nakatake
-
Publication number: 20220143263Abstract: Provided is a thrombin-carrying hemostatic sheet that is suitable for hemostasis during surgery, in particular, for hemostasis during spine surgery, that is convenient without preparation before use, and that is bioabsorbable and can be embedded in the body as it is. The hemostatic sheet is composed of a gelatin sponge carrying an effective amount of thrombin, wherein (A) the density is 30 to 55 mg/cm3, and (B) the shape maintaining angle in wet conditions is 55 to 120°.Type: ApplicationFiled: March 19, 2020Publication date: May 12, 2022Applicants: Astellas Pharma Inc., National University Corporation Tokyo Medical and Dental UniversityInventors: Makoto OGINO, Keiichi YOSHIHARA, Yasuharu KIMURA, Megumi AOKI, Toshitaka YOSHII, Satoru EGAWA
-
Patent number: 11312966Abstract: [Problem] To provide a nucleic acid expected to be useful for treating mite allergy. [Means to be solved] Provided is a nucleic acid comprising a nucleotide sequence encoding a chimeric protein, wherein the nucleic acid comprises a nucleotide sequence encoding a signal peptide, a nucleotide sequence encoding an intra-organelle stabilizing domain of LAMP, a nucleotide sequence encoding an allergen domain comprising Der p 1, Der p 2, Der p 23, and Der p 7, a nucleotide sequence encoding a transmembrane domain and a nucleotide sequence encoding an endosomal/lysosomal targeting domain of LAMP in this order.Type: GrantFiled: July 15, 2021Date of Patent: April 26, 2022Assignee: Astellas Pharma Inc.Inventors: Takanori Marui, Masao Uchida
-
Patent number: 11286459Abstract: An object of the present invention is to provide an animal cell culture method which is high in protein productivity. Provided is a method for culturing animal cells in a culture medium, wherein the culture medium comprises a nucleic acid component(s) (deoxyuridine, thymidine, and/or deoxycytidine, or a salt(s) thereof). Also provided is a method for producing a protein, the method comprising the step of culturing animal cells expressing the protein in a culture medium, wherein the culture medium comprises a nucleic acid component(s).Type: GrantFiled: May 26, 2016Date of Patent: March 29, 2022Assignee: Astellas Pharma Inc.Inventors: Yasuhiro Takagi, Takuya Kikuchi
-
Publication number: 20220089455Abstract: [Problem] A novel method for producing a nanoparticle having a metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded is provided, where the nanoparticle is useful as a contrast agent for magnetic resonance imaging. [Means for Solution] As the novel method for producing a nanoparticle having a metal particle which contains iron oxide to which one or more hydrophilic ligands are coordination bonded, by performing ligand exchange to a hydrophilic ligand from an iron oxide nanoparticle having a surface to which a hydrophobic ligand is coordination bonded in one step using a phase transfer catalyst, it is possible to expect shortening of production processes and reduction of hydrophilic ligands used. Furthermore, by producing an iron oxide nanoparticle having a surface to which a hydrophobic ligand is coordination bonded using a dropwise addition method, it is possible to avoid a rapid temperature rise and a reaction at a high temperature of 200° C.Type: ApplicationFiled: December 27, 2019Publication date: March 24, 2022Applicant: ASTELLAS PHARMA INC.Inventors: Takashi KIKUCHI, Tsuyoshi MIZUTANI, Hiroki TOYA, Akio KURODA, Yota GOTO, Shun HIRASAWA, Toshiyuki SUGIMORI
-
Patent number: 11279757Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.Type: GrantFiled: September 5, 2018Date of Patent: March 22, 2022Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbhInventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
-
Patent number: 11260124Abstract: To provide a superior anti-human NGF antibody Fab fragment that maintains a high neutralizing activity, and that reduces systemic side-effects arising from systemic exposure while expressing a local drug effect, and means for treating postoperative pain by using such antibody fragment. An anti-human NGF antibody Fab fragment comprising a heavy-chain fragment consisting of the amino acid sequence shown by SEQ ID NO:5 and a light-chain consisting of the amino acid sequence shown by SEQ ID NO: 8.Type: GrantFiled: May 20, 2016Date of Patent: March 1, 2022Assignee: Astellas Pharma Inc.Inventors: Hirotsugu Tanaka, Hirotada Fujita, Toshiaki Aoki
-
Publication number: 20220023422Abstract: Provided is a stable pharmaceutical composition, comprising an anti-human TSLP receptor antibody, capable of inhibiting the generation of chemically modified substances, such as deamidated forms and oxidized forms, or degradants or multimers. The pharmaceutical composition comprises an anti-human TSLP receptor antibody, a pharmaceutically acceptable buffer, arginine or a pharmaceutically acceptable salt thereof, and a surfactant.Type: ApplicationFiled: February 10, 2021Publication date: January 27, 2022Applicant: ASTELLAS PHARMA INC.Inventors: Megumi IKEDA, Akinori CHIKUSHI
-
Publication number: 20220016239Abstract: [Problem to be Solved] Provided is an effective and safe method for treating or preventing a cancer using aAVC. [Solution] The present invention finds suitable ranges of the dose of ?-GalCer loaded on aAVC cell surface, and the amount of ?-GalCer loaded on aAVC cell surface in a pharmaceutical composition comprising aAVC, which are preferred in terms of securing effectiveness and safety in the treatment and prevention of a cancer using aAVC, and provides an effective and safe method for treating or preventing a cancer using aAVC, aAVC for effective and safe treatment or prevention of a cancer, and a pharmaceutical composition comprising the same, etc.Type: ApplicationFiled: December 1, 2020Publication date: January 20, 2022Applicants: ASTELLAS PHARMA INC., RIKENInventors: Keisuke OHSUMI, Taku YOSHIDA, Masayuki KANKI, Shinichiro FUJII, Kanako SHIMIZU
-
Patent number: 11225642Abstract: The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGF? signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells.Type: GrantFiled: June 11, 2014Date of Patent: January 18, 2022Assignees: Kyoto University, Astellas Pharma Inc.Inventors: Kenji Osafune, Takafumi Toyohara, Yukiko Yamagishi
-
Patent number: RE49111Abstract: [Problem] To provide a compound which is useful as an active ingredient for a pharmaceutical composition for preventing or treating urine storage dysfunction, voiding dysfunction, lower urinary tract dysfunction, and the like. [Means for Solution] The present inventors have found that a thiazole derivative substituted with pyrazinylcarbonylamino at the 2-position is an excellent muscarinic M3 receptor-positive allosteric modulator and is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, thereby completing the present invention. 2-Acylaminothiazole derivative or a salt thereof of the present invention is expected as an agent for preventing or treating bladder/urinary tract diseases associated with bladder contractions via a muscarinic M3 receptor, for example voiding dysfunction such as underactive bladder.Type: GrantFiled: April 23, 2020Date of Patent: June 21, 2022Assignee: ASTELLAS PHARMA INC.Inventors: Taisuke Takahashi, Takanori Koike, Kenji Negoro, Hiroaki Tanaka, Jun Maeda, Kazuhiro Yokoyama, Hajime Takamatsu